← Back to Search

NMDA Receptor Antagonist

Ketamine for Acute Pain

Phase 4
Recruiting
Led By Michael Pallaci, DO, FACEP
Research Sponsored by Summa Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Primary complaint of acute moderate to severe pain on VAS/numeric pain scale (a score of ≥5cm which corresponds to 50mm)
Must be alert and oriented times three
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes
Awards & highlights

Study Summary

This trial is studying whether a longer or shorter infusion of ketamine reduces side effects in people with severe pain in the emergency department.

Who is the study for?
This trial is for adults over 18 in the Emergency Department with acute, severe pain from conditions like abdominal or musculoskeletal pain. They must be alert, oriented, and able to consent. Excluded are pregnant or breastfeeding individuals, those with altered mental status or unstable vitals, recent drug/alcohol use, certain psychiatric conditions, recent analgesic use, chronic opiate users, and those with specific heart diseases.Check my eligibility
What is being tested?
The study tests if a low dose of Ketamine given slowly through an IV over 30 minutes reduces side effects compared to a faster infusion over 15 minutes while still controlling severe pain effectively in emergency situations.See study design
What are the potential side effects?
Ketamine may cause side effects such as feelings of dissociation (feeling detached from reality), changes in blood pressure and heart rate, nausea or vomiting. The trial aims to see if slower infusion rates can reduce these potential side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My pain level is at least a 5 out of 10.
Select...
I am fully aware of who I am, where I am, and the current time.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) Score
Secondary outcome measures
Visual Analog Scale (VAS) Score

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Ketamine 30 MinutesExperimental Treatment1 Intervention
Participants receive 0.25mg/kg Ketamine dose intravenous for pain over 30 minutes.
Group II: Ketamine 15 MinutesActive Control1 Intervention
Participants receive 0.25mg/kg Ketamine dose intravenous for pain over 15 minutes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
2011
Completed Phase 4
~1090

Find a Location

Who is running the clinical trial?

Summa Health SystemLead Sponsor
30 Previous Clinical Trials
3,147 Total Patients Enrolled
Michael Pallaci, DO, FACEPPrincipal InvestigatorSumma Health System

Media Library

Ketamine (NMDA Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05518877 — Phase 4
Acute Pain Research Study Groups: Ketamine 15 Minutes, Ketamine 30 Minutes
Acute Pain Clinical Trial 2023: Ketamine Highlights & Side Effects. Trial Name: NCT05518877 — Phase 4
Ketamine (NMDA Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05518877 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA certified Ketamine for medicinal use?

"There is ample evidence in favor of Ketamine's safety, thus it has earned a rating of 3."

Answered by AI

May I be considered for participation in this scientific experiment?

"This clinical trial seeks 48 participants aged 18 to 65 who suffer from acute pain. Those wishing to participate should meet the following conditions: present a VAS/ numeric pain scale score of at least 5cm (50mm), have symptoms localized in the abdominal, flank, back, musculoskeletal or traumatic chest areas, be mentally lucid and able to provide consent."

Answered by AI

Does this investigation accept participants over the age of 50?

"Eligibility for this clinical trial necessitates a patient to be within the ages of 18 and 65. There are 60 investigations available to minors while older participants can join 281 studies."

Answered by AI

Are there any spots available for this investigation at present?

"According to clinicaltrials.gov, this medical trial is not presently looking for more patients. The study's initial posting was on November 15th 2022 and its most recent modification occurred on September 24th 2022. During this period of inactivity, there are 346 other trials actively seeking participants."

Answered by AI
~10 spots leftby Aug 2024